Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
126.60    2.40 (1.93%)
Bid:
125.40
Ask:
126.20
Spread: 0.80 (0.638%)
Market Cap: £308.17m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Director Declaration

10 Nov 2022 17:00

RNS Number : 0398G
PureTech Health PLC
10 November 2022
 

10 November 2022

 PureTech Health plc

 

Director Declaration

 

Pursuant to Listing Rule 9.6.14(2), PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") notes that Christopher Viehbacher, a Non-Executive Director and Chair of the Company's Board, has been appointed as President and Chief Executive Officer and a member of the Board of Biogen Inc. (Nasdaq: BIIB) with effect from November 14, 2022. 

 

For further information please contact:

Bharatt Chowrira, PhD, JD, President and Chief Business, Finance and Operating Officer, member of the Board of Directors and Company Secretary: +1 617 482 2333

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNEAKFEFFPAFFA
Date   Source Headline
25th Apr 202311:50 amRNSVedanta Gets $106M+ to Advance Microbiome Pipeline
25th Apr 20237:00 amRNSTransaction in Own Shares
24th Apr 20237:00 amRNSTransaction in Own Shares
21st Apr 20237:00 amRNSTransaction in Own Shares
20th Apr 20237:00 amRNSTransaction in Own Shares
19th Apr 20237:00 amRNSTransaction in Own Shares
18th Apr 20237:00 amRNSTransaction in Own Shares
17th Apr 20237:05 amRNSVedanta Publishes VE303 Phase 2 Results in JAMA
17th Apr 20237:00 amRNSTransaction in Own Shares
14th Apr 20237:00 amRNSTransaction in Own Shares
13th Apr 20237:00 amRNSNotice of Results
13th Apr 20237:00 amRNSTransaction in Own Shares
12th Apr 20237:00 amRNSTransaction in Own Shares
11th Apr 20237:00 amRNSTransaction in Own Shares
6th Apr 20237:00 amRNSTransaction in Own Shares
5th Apr 20237:00 amRNSTransaction in Own Shares
4th Apr 20237:00 amRNSTransaction in Own Shares
3rd Apr 20237:00 amRNSTransaction in Own Shares
31st Mar 20237:00 amRNSTransaction in Own Shares
30th Mar 20237:00 amRNSTransaction in Own Shares
28th Mar 20237:00 amRNSTransaction in Own Shares
23rd Mar 20237:00 amRNSPRTC Gets Up To $500M From RPRX For KarXT Royalty
23rd Mar 20237:00 amRNSTransaction in Own Shares
22nd Mar 20231:10 pmRNSTransaction in Own Shares
21st Mar 20237:00 amRNSTransaction in Own Shares
20th Mar 202311:42 amRNSKaruna 2nd Successful Ph3 Study in Schizophrenia
20th Mar 20237:00 amRNSTransaction in Own Shares
17th Mar 20237:00 amRNSTransaction in Own Shares
16th Mar 20237:00 amRNSTransaction in Own Shares
15th Mar 20237:00 amRNSTransaction in Own Shares
14th Mar 20237:00 amRNSTransaction in Own Shares
13th Mar 20237:00 amRNSTransaction in Own Shares
10th Mar 20237:00 amRNSTransaction in Own Shares
9th Mar 20237:00 amRNSTransaction in Own Shares
8th Mar 20237:00 amRNSTransaction in Own Shares
7th Mar 20237:00 amRNSTransaction in Own Shares
6th Mar 20237:00 amRNSTransaction in Own Shares
3rd Mar 20237:00 amRNSTransaction in Own Shares
2nd Mar 20237:00 amRNSTransaction in Own Shares
1st Mar 202312:00 pmRNSPureTech to Present at Barclays Healthcare Conf
1st Mar 20237:00 amRNSTransaction in Own Shares
28th Feb 20237:00 amRNSTransaction in Own Shares
27th Feb 20232:09 pmRNSSonde & MGH Lead Study on Frontotemporal Disorders
27th Feb 20237:00 amRNSTransaction in Own Shares
24th Feb 20237:00 amRNSTransaction in Own Shares
23rd Feb 20237:00 amRNSTransaction in Own Shares
22nd Feb 20237:00 amRNSTransaction in Own Shares
21st Feb 20237:00 amRNSTransaction in Own Shares
20th Feb 20237:00 amRNSTransaction in Own Shares
17th Feb 20235:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.